Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Clinically Isolated Syndrome and Early Relapsing Multiple Sclerosis.

Metz LM.

Continuum (Minneap Minn). 2019 Jun;25(3):670-688. doi: 10.1212/CON.0000000000000729.

PMID:
31162311
2.

Focus on the gut-brain axis: Multiple sclerosis, the intestinal barrier and the microbiome.

Camara-Lemarroy CR, Metz LM, Yong VW.

World J Gastroenterol. 2018 Oct 7;24(37):4217-4223. doi: 10.3748/wjg.v24.i37.4217.

3.

Ischemic Strokes in a Man with Congenital Afibrinogenemia.

Nathoo N, Rydz N, Poon MC, Metz LM.

Can J Neurol Sci. 2018 Sep;45(5):590-592. doi: 10.1017/cjn.2018.57. Epub 2018 Jul 18. No abstract available.

PMID:
30019658
4.

Effective treatment of progressive MS remains elusive.

Metz LM, Liu WQ.

Lancet. 2018 Mar 31;391(10127):1239-1240. doi: 10.1016/S0140-6736(18)30426-4. Epub 2018 Mar 23. No abstract available.

PMID:
29576503
5.

Global transcriptome profiling of mild relapsing-remitting versus primary progressive multiple sclerosis.

Koch MW, Ilnytskyy Y, Golubov A, Metz LM, Yong VW, Kovalchuk O.

Eur J Neurol. 2018 Apr;25(4):651-658. doi: 10.1111/ene.13565. Epub 2018 Feb 13.

PMID:
29316044
6.

Discriminative ability of quality of life measures in multiple sclerosis.

Fiest KM, Greenfield J, Metz LM, Patten SB, Jetté N, Marrie RA.

Health Qual Life Outcomes. 2017 Dec 21;15(1):246. doi: 10.1186/s12955-017-0828-0.

7.

Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?

Faissner S, Mahjoub Y, Mishra M, Haupeltshofer S, Hahn JN, Gold R, Koch M, Metz LM, Ben-Hur T, Yong VW.

Mult Scler. 2018 Oct;24(12):1543-1556. doi: 10.1177/1352458517728811. Epub 2017 Aug 31.

PMID:
28857721
8.

Trial of Minocycline in Clinically Isolated Syndrome of Multiple Sclerosis.

Metz LM, Eliasziw M.

N Engl J Med. 2017 Aug 24;377(8):789. doi: 10.1056/NEJMc1708486. No abstract available.

PMID:
28834477
9.

Hospitalization is associated with subsequent disability in multiple sclerosis.

Garland A, Metz LM, Bernstein CN, Peschken CA, Hitchon CA, Marrie RA.

Mult Scler Relat Disord. 2017 May;14:23-28. doi: 10.1016/j.msard.2017.03.009. Epub 2017 Mar 24.

10.

Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis.

Metz LM, Li DKB, Traboulsee AL, Duquette P, Eliasziw M, Cerchiaro G, Greenfield J, Riddehough A, Yeung M, Kremenchutzky M, Vorobeychik G, Freedman MS, Bhan V, Blevins G, Marriott JJ, Grand'Maison F, Lee L, Thibault M, Hill MD, Yong VW; Minocycline in MS Study Team.

N Engl J Med. 2017 Jun 1;376(22):2122-2133. doi: 10.1056/NEJMoa1608889.

11.

Gestational bisphenol-A exposure lowers the threshold for autoimmunity in a model of multiple sclerosis.

Rogers JA, Mishra MK, Hahn J, Greene CJ, Yates RM, Metz LM, Yong VW.

Proc Natl Acad Sci U S A. 2017 May 9;114(19):4999-5004. doi: 10.1073/pnas.1620774114. Epub 2017 Apr 24.

12.

Smoking does not influence disability accumulation in primary progressive multiple sclerosis.

Javizian O, Metz LM, Deighton S, Koch MW.

Eur J Neurol. 2017 Apr;24(4):624-630. doi: 10.1111/ene.13262. Epub 2017 Feb 26.

PMID:
28239937
13.

Medical Tourism for CCSVI Procedures in People with Multiple Sclerosis: An Observational Study.

Metz LM, Greenfield J, Marrie RA, Jette N, Blevins G, Svenson LW, Alikhani K, Wall W, Dhaliwal R, Suchowersky O.

Can J Neurol Sci. 2016 May;43(3):360-7. doi: 10.1017/cjn.2015.350. Epub 2016 Feb 4.

PMID:
26891024
14.

Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes.

Zhornitsky S, McKay KA, Metz LM, Teunissen CE, Rangachari M.

Mult Scler Relat Disord. 2016 Jan;5:53-65. doi: 10.1016/j.msard.2015.10.005. Epub 2015 Oct 19. Review.

PMID:
26856944
15.

Multi-scale MRI spectrum detects differences in myelin integrity between MS lesion types.

Zhang Y, Jonkman L, Klauser A, Barkhof F, Yong VW, Metz LM, Geurts JJ.

Mult Scler. 2016 Oct;22(12):1569-1577. Epub 2016 Jan 11.

PMID:
26754802
16.

1,25-Dihydroxyvitamin D3 Protects against Immune-Mediated Killing of Neurons in Culture and in Experimental Autoimmune Encephalomyelitis.

Sloka S, Zhornitsky S, Silva C, Metz LM, Yong VW.

PLoS One. 2015 Dec 17;10(12):e0144084. doi: 10.1371/journal.pone.0144084. eCollection 2015.

17.

Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring.

Traboulsee A, Létourneau-Guillon L, Freedman MS, O'Connor PW, Bharatha A, Chakraborty S, Girard JM, Giuliani F, Lysack JT, Marriott JJ, Metz LM, Morrow SA, Oh J, Sharma M, Vandorpe RA, Vertinsky TA, Wadhwa VS, von Riedemann S, Li DK.

Can J Neurol Sci. 2015 May;42(3):159-67. doi: 10.1017/cjn.2015.24. Epub 2015 Apr 21.

18.

Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis.

Zhornitsky S, Johnson TA, Metz LM, Weiss S, Yong VW.

J Neuroinflammation. 2015 Mar 19;12:55. doi: 10.1186/s12974-015-0278-8.

19.

Predictors of chronic cerebrospinal venous insufficiency procedure use among older people with multiple sclerosis: a national case-control study.

Ploughman M, Manning OJ, Beaulieu S, Harris C, Hogan SH, Mayo N, Fisk JD, Sadovnick AD, O'Connor P, Morrow SA, Metz LM, Smyth P, Allderdice PW, Scott S, Marrie RA, Stefanelli M, Godwin M.

BMC Health Serv Res. 2015 Apr 16;15:161. doi: 10.1186/s12913-015-0835-y.

20.

Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.

Zhornitsky S, Greenfield J, Koch MW, Patten SB, Harris C, Wall W, Alikhani K, Burton J, Busche K, Costello F, Davenport JW, Jarvis SE, Lavarato D, Parpal H, Patry DG, Yeung M, Metz LM.

PLoS One. 2015 Apr 13;10(4):e0123824. doi: 10.1371/journal.pone.0123824. eCollection 2015.

21.

Serum NSE level and disability progression in multiple sclerosis.

Koch MW, George S, Wall W, Wee Yong V, Metz LM.

J Neurol Sci. 2015 Mar 15;350(1-2):46-50. doi: 10.1016/j.jns.2015.02.009. Epub 2015 Feb 11.

PMID:
25686504
22.

Validity of four screening scales for major depression in MS.

Patten SB, Burton JM, Fiest KM, Wiebe S, Bulloch AG, Koch M, Dobson KS, Metz LM, Maxwell CJ, Jetté N.

Mult Scler. 2015 Jul;21(8):1064-71. doi: 10.1177/1352458514559297. Epub 2015 Jan 12.

PMID:
25583846
23.

The natural history of early versus late disability accumulation in primary progressive MS.

Koch MW, Greenfield J, Javizian O, Deighton S, Wall W, Metz LM.

J Neurol Neurosurg Psychiatry. 2015 Jun;86(6):615-21. doi: 10.1136/jnnp-2014-307948. Epub 2014 Aug 4.

PMID:
25091366
24.

MRI texture heterogeneity in the optic nerve predicts visual recovery after acute optic neuritis.

Zhang Y, Metz LM, Scott JN, Trufyn J, Fick GH, Costello F.

Neuroimage Clin. 2014 Jan 14;4:302-7. doi: 10.1016/j.nicl.2014.01.003. eCollection 2014.

25.

The Canadian survey of health, lifestyle and ageing with multiple sclerosis: methodology and initial results.

Ploughman M, Beaulieu S, Harris C, Hogan S, Manning OJ, Alderdice PW, Fisk JD, Sadovnick AD, O'Connor P, Morrow SA, Metz LM, Smyth P, Mayo N, Marrie RA, Knox KB, Stefanelli M, Godwin M.

BMJ Open. 2014 Jul 10;4(7):e005718. doi: 10.1136/bmjopen-2014-005718. Erratum in: BMJ Open. 2015;5(3):e005718.

26.

Detection of reduced interhemispheric cortical communication during task execution in multiple sclerosis patients using functional near-infrared spectroscopy.

Jimenez JJ, Yang R, Nathoo N, Varshney VP, Golestani AM, Goodyear BG, Metz LM, Dunn JF.

J Biomed Opt. 2014;19(7):076008. doi: 10.1117/1.JBO.19.7.076008.

PMID:
25003756
27.

Depression in multiple sclerosis: a long-term longitudinal study.

Koch MW, Patten S, Berzins S, Zhornitsky S, Greenfield J, Wall W, Metz LM.

Mult Scler. 2015 Jan;21(1):76-82. doi: 10.1177/1352458514536086. Epub 2014 May 22.

PMID:
24852924
28.

Hand dexterity and direct disease related cost in multiple sclerosis.

Koch MW, Murray TJ, Fisk J, Greenfield J, Bhan V, Jacobs P, Brown M, Metz LM.

J Neurol Sci. 2014 Jun 15;341(1-2):51-4. doi: 10.1016/j.jns.2014.03.047. Epub 2014 Apr 2.

PMID:
24768310
29.

Depression as a predictor of occupational transition in a multiple sclerosis cohort.

Patten SB, Williams JV, Lavorato DH, Koch M, Metz LM.

Funct Neurol. 2013 Oct-Dec;28(4):275-80. doi: 10.11138/FNeur/2013.28.4.275.

30.

Point prevalence and correlates of depression in a national community sample with multiple sclerosis.

Viner R, Fiest KM, Bulloch AG, Williams JV, Lavorato DH, Berzins S, Jetté N, Metz LM, Patten SB.

Gen Hosp Psychiatry. 2014 May-Jun;36(3):352-4. doi: 10.1016/j.genhosppsych.2013.12.011. Epub 2014 Jan 13.

PMID:
24559790
31.

Application and a proposed modification of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Canadian cohort of patients with clinically isolated syndromes.

Kang H, Metz LM, Traboulsee AL, Eliasziw M, Zhao GJ, Cheng Y, Zhao Y, Li DK; Minocycline in CIS Study Group.

Mult Scler. 2014 Apr;20(4):458-63. doi: 10.1177/1352458513501230. Epub 2013 Aug 22.

PMID:
23970502
32.

Treatment trials in progressive MS--current challenges and future directions.

Koch MW, Cutter G, Stys PK, Yong VW, Metz LM.

Nat Rev Neurol. 2013 Sep;9(9):496-503. doi: 10.1038/nrneurol.2013.148. Epub 2013 Jul 30. Review.

PMID:
23897406
33.

Quetiapine fumarate for the treatment of multiple sclerosis: focus on myelin repair.

Zhornitsky S, Wee Yong V, Koch MW, Mackie A, Potvin S, Patten SB, Metz LM.

CNS Neurosci Ther. 2013 Oct;19(10):737-44. doi: 10.1111/cns.12154. Epub 2013 Jul 22. Review.

PMID:
23870612
34.

Reduction of microglial activity in a model of multiple sclerosis by dipyridamole.

Sloka S, Metz LM, Hader W, Starreveld Y, Yong VW.

J Neuroinflammation. 2013 Jul 18;10:89. doi: 10.1186/1742-2094-10-89.

35.

CRYAB modulates the activation of CD4+ T cells from relapsing-remitting multiple sclerosis patients.

Quach QL, Metz LM, Thomas JC, Rothbard JB, Steinman L, Ousman SS.

Mult Scler. 2013 Dec;19(14):1867-77. doi: 10.1177/1352458513489853. Epub 2013 Jun 4.

PMID:
23736536
36.

Epigenetic changes in patients with multiple sclerosis.

Koch MW, Metz LM, Kovalchuk O.

Nat Rev Neurol. 2013 Jan;9(1):35-43. doi: 10.1038/nrneurol.2012.226. Epub 2012 Nov 20. Review.

PMID:
23165337
37.

Environmental factors and their regulation of immunity in multiple sclerosis.

Koch MW, Metz LM, Agrawal SM, Yong VW.

J Neurol Sci. 2013 Jan 15;324(1-2):10-6. doi: 10.1016/j.jns.2012.10.021. Epub 2012 Nov 13. Review.

PMID:
23154080
38.

Epigenetics and miRNAs in the diagnosis and treatment of multiple sclerosis.

Koch MW, Metz LM, Kovalchuk O.

Trends Mol Med. 2013 Jan;19(1):23-30. doi: 10.1016/j.molmed.2012.10.008. Epub 2012 Nov 12. Review.

PMID:
23153574
39.

Evaluation of the 9-item Patient Health Questionnaire (PHQ-9) as an assessment instrument for symptoms of depression in patients with multiple sclerosis.

Sjonnesen K, Berzins S, Fiest KM, M Bulloch AG, Metz LM, Thombs BD, Patten SB.

Postgrad Med. 2012 Sep;124(5):69-77. doi: 10.3810/pgm.2012.09.2595.

PMID:
23095427
40.

Prolactin in multiple sclerosis.

Zhornitsky S, Yong VW, Weiss S, Metz LM.

Mult Scler. 2013 Jan;19(1):15-23. doi: 10.1177/1352458512458555. Epub 2012 Aug 29. Review.

PMID:
22933621
41.

Disability in a community population with MS with and without mental disorders.

Patten SB, Williams JV, Lavorato DH, Metz LM, Bulloch AG.

Int J Psychiatry Med. 2012;43(1):51-65.

PMID:
22641930
42.

Perceived met and unmet health-care needs in a community population with multiple sclerosis.

Patten SB, Williams JV, Lavorato DH, Terriff D, Metz LM, Berzins S, Bulloch AG.

Int J MS Care. 2012 Spring;14(1):2-8. doi: 10.7224/1537-2073-14.1.2.

43.

Health status, stress and life satisfaction in a community population with MS.

Patten SB, Williams JV, Lavorato DH, Berzins S, Metz LM, Bulloch AG.

Can J Neurol Sci. 2012 Mar;39(2):206-12.

PMID:
22343155
44.

Texture analysis differentiates persistent and transient T1 black holes at acute onset in multiple sclerosis: a preliminary study.

Zhang Y, Traboulsee A, Zhao Y, Metz LM, Li DK.

Mult Scler. 2011 May;17(5):532-40. doi: 10.1177/1352458510395981. Epub 2011 Jan 26.

PMID:
21270058
45.

Corpus callosum volume and interhemispheric transfer in multiple sclerosis.

Brown LN, Zhang Y, Mitchell JR, Zabad R, Metz LM.

Can J Neurol Sci. 2010 Sep;37(5):615-9.

PMID:
21059507
46.

Dominant perivenular enhancement of tumefactive demyelinating lesions in multiple sclerosis.

Zhang Y, Metz LM.

Neurology. 2010 Oct 12;75(15):1396. doi: 10.1212/WNL.0b013e3181f736d3. No abstract available.

PMID:
20938034
47.

3T deep gray matter T2 hypointensity correlates with disability over time in stable relapsing-remitting multiple sclerosis: a 3-year pilot study.

Zhang Y, Metz LM, Yong VW, Mitchell JR.

J Neurol Sci. 2010 Oct 15;297(1-2):76-81. doi: 10.1016/j.jns.2010.07.014. Epub 2010 Aug 12.

PMID:
20708201
48.

Challenges in screening for depression in multiple sclerosis.

Patten SB, Berzins S, Metz LM.

Mult Scler. 2010 Nov;16(11):1406-11. doi: 10.1177/1352458510377770. Epub 2010 Aug 4.

PMID:
20685765
49.

Neuroinflammation and demyelination in multiple sclerosis after allogeneic hematopoietic stem cell transplantation.

Lu JQ, Joseph JT, Nash RA, Storek J, Stevens AM, Metz LM, Clark AW, Johnson ES, Yong VW.

Arch Neurol. 2010 Jun;67(6):716-22. doi: 10.1001/archneurol.2010.117.

PMID:
20558390
50.

Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.

Metz LM, Li D, Traboulsee A, Myles ML, Duquette P, Godin J, Constantin M, Yong VW; GA/minocycline study investigators.

Mult Scler. 2009 Oct;15(10):1183-94. doi: 10.1177/1352458509106779. Epub 2009 Sep 23.

PMID:
19776092

Supplemental Content

Support Center